News
HC Wainwright & Co. Reiterates Buy on Verastem, Maintains $17.5 Price Target
19 Mar 24
News, Price Target, Reiteration, Analyst Ratings
RBC Capital Reiterates Outperform on Verastem, Maintains $32 Price Target
15 Mar 24
News, Price Target, Reiteration, Analyst Ratings
Recap: Verastem Q4 Earnings
14 Mar 24
Earnings
Verastem Q4 2023 Adj EPS $(1.10) Misses $(0.62) Estimate
14 Mar 24
Earnings, Earnings Misses, News
Verastem Oncology Announces Multiple Oral Presentations At Society Of Gynecologic Oncology 2024 Annual Meeting On Women's Cancer
11 Mar 24
Biotech, News, Health Care, General
Verastem Oncology Secures FDA Orphan Drug Designation For Avutometinib Alone Or In Combination With Defactinib In Recurrent Low-Grade Serous Ovarian Cancer
5 Mar 24
News, FDA
Verastem Oncology Announces Preclinical Presentations For New Oral G12D Inhibitor And For Avutometinib And Defactinib Combination As A Backbone Of Therapy For RAS/MAPK Driven Cancers At AACR Annual Meeting 2024
5 Mar 24
Biotech, News, General
Why Big Lots Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session
12 Feb 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers
29 Jan 24
News
Press releases
GenFleet Therapeutics Announces Potent Anti-tumor Efficacy of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, and its Potential in Combination Therapy with RAF/MEK Clamp at 2024 AACR Annual Meeting
9 Apr 24
Press Releases
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4 Apr 24
Press Releases
Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women's Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs
11 Mar 24
Press Releases
Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
5 Mar 24
Press Releases
Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024
5 Mar 24
Press Releases